Results 11 to 20 of about 5,865,913 (286)

Relationship Between Nonalcoholic Fatty Liver Disease and Severity of Coronary Artery Disease in Patients Undergoing Coronary Angiography

Archives of Basic and Clinical Research
Objective: Nonalcoholic fatty liver disease has been connected to coronary artery disease, which is the main cause of mortality. The connection between the degree of nonalcoholic fatty liver disease-induced liver fibrosis and the severity of coronary ...
Tayyip İlker Aydın, Şevket Kahraman, Halil İbrahim Tanrıseven, Emin Murat Akbaş   +3 more
doaj   +2 more sources

A Plasma Exosomal Metabolic Profiling of Nonalcoholic Fatty Liver Disease Patients Complicated with Impaired Fasting Glucose

The Turkish Journal of Gastroenterology
Background/Aims: Nonalcoholic fatty liver disease is considered as the hepatic manifestation of metabolic syndrome. Detection of circulating exosomes together with metabolomic analysis of their cargo would provide early signals for metabolic derangements
Weiyun Jiang, Qiaofei Jin, Chunqing Li, Yunhao Xun   +3 more
doaj   +2 more sources

ANTIOXIDANTS AS POTENTIAL BIOMARKERS OF NONALCOHOLIC FATTY LIVER DISEASE STAGES

Байкальский медицинский журнал, 2023
Nonalcoholic fatty liver disease is a complex and multifactorial pathology associated with multiple epigenetic, genetic and environmental factors, and its pathogenesis is still not fully understood.
Sofya D. Kravchenko, Natalia M. Kozlova, Olesya V. Tirikova, Vera Il. Bakhtairova   +3 more
doaj   +1 more source

A dual-responsive fluorescent probe for imaging viscosity and polarity in nonalcoholic fatty liver disease. [PDF]

Smart Mol
We developed a BODIPY‐based fluorescent probe with dual responsiveness to viscosity and polarity, enabling sensitive and precise imaging of non‐alcoholic fatty liver disease. Abstract Viscosity and polarity are critical physiological parameters implicated in the onset and progression of nonalcoholic fatty liver disease (NAFLD).
Zhao D, Wang Z, Xu K, Liu Y, Wu D, Jiang T, Gao H, Xiao C, Zheng D, Wang K, Zhai W.   +10 more
europepmc   +2 more sources

Nonalcoholic fatty liver disease and cardiovascular disease phenotypes

SAGE Open Medicine, 2020
Nonalcoholic fatty liver disease is increasingly recognized as a major global health problem. Intertwined with diabetes, metabolic syndrome, and obesity, nonalcoholic fatty liver disease embraces a spectrum of liver conditions spanning from steatosis to ...
Giandomenico Bisaccia, Fabrizio Ricci, Cesare Mantini, Claudio Tana, Gian Luca Romani, Cosima Schiavone, Sabina Gallina   +6 more
doaj   +1 more source

Treatments for NAFLD [PDF]

Farmacja Polska, 2021
Non-alcoholic fatty liver disease (NAFLD) is categorised into simple steatosis, termed nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH).
Katarzyna Juszczyńska
doaj   +1 more source

Intestinal peroxisome proliferator‐activated receptor α‐fatty acid‐binding protein 1 axis modulates nonalcoholic steatohepatitis

Hepatology, EarlyView., 2022
Abstract Background and Aims Peroxisome proliferator‐activated receptor α (PPARα) regulates fatty acid transport and catabolism in liver. However, the role of intestinal PPARα in lipid homeostasis is largely unknown. Here, intestinal PPARα was examined for its modulation of obesity and NASH. Approach and Results Intestinal PPARα was activated and fatty
Tingting Yan, Yuhong Luo, Nana Yan, Keisuke Hamada, Nan Zhao, Yangliu Xia, Ping Wang, Changdong Zhao, Dan Qi, Shoumei Yang, Lulu Sun, Jie Cai, Qiong Wang, Changtao Jiang, Oksana Gavrilova, Kristopher W. Krausz, Daxesh P. Patel, Xiaoting Yu, Xuan Wu, Haiping Hao, Weiwei Liu, Aijuan Qu, Frank J. Gonzalez   +22 more
wiley   +1 more source

Lipocalin‐2 activates hepatic stellate cells and promotes nonalcoholic steatohepatitis in high‐fat diet–fed Ob/Ob mice

Hepatology, EarlyView., 2022
Graphical summary of obesity‐induced NASH progression by LCN2 targeted to HSC activation. Abstract Background and Aims In obesity and type 2 diabetes mellitus, leptin promotes insulin resistance and contributes to the progression of NASH via activation of hepatic stellate cells (HSCs).
Kyung Eun Kim, Jaewoong Lee, Hyun Joo Shin, Eun Ae Jeong, Hye Min Jang, Yu Jeong Ahn, Hyeong Seok An, Jong Youl Lee, Meong Cheol Shin, Soo Kyoung Kim, Won Gi Yoo, Won Ho Kim, Gu Seob Roh   +12 more
wiley   +1 more source

Integrative evidence construction for resveratrol treatment of nonalcoholic fatty liver disease: preclinical and clinical meta-analyses

Frontiers in Pharmacology, 2023
Background: Resveratrol, a polyphenol found in various plants, is known for its diverse bioactivities and has been explored in relation to nonalcoholic fatty liver disease (NAFLD). However, no high-quality evidence exists regarding its efficacy.Objective:
Xuan He, Yubing Li, Xinyu Deng, Xiaolin Xiao, Jinhao Zeng   +4 more
doaj   +1 more source

IL‐31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH

Hepatology, EarlyView., 2022
IL‐31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases Abstract Background and Aims Pruritus is associated with multiple liver diseases, particularly those with cholestasis, but the mechanism remains incompletely understood.
Jun Xu, Ya Wang, Mina Khoshdeli, Matt Peach, Jen‐Chieh Chuang, Julie Lin, Wen‐Wei Tsai, Sangeetha Mahadevan, Wesley Minto, Lauri Diehl, Ruchi Gupta, Michael Trauner, Keyur Patel, Mazen Noureddin, Kris V. Kowdley, Aliya Gulamhusein, Christopher L. Bowlus, Ryan S. Huss, Robert P. Myers, Chuhan Chung, Andrew N. Billin   +20 more
wiley   +1 more source